Affichage 1 à 7 des 7 essais cliniques
ESSAIS CLINIQUES
    No essai
    ClinicalTrials.gov ID
Phase Coordonnateur(rice)
(EN) A Phase 2/3 Multicenter, Open-label, 3-arm, 2-Stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia With FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy
    2215-CL-0201
    NCT02752035
     Actif en recrutement
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
Phase II Lorena Iglesias
514-934-1934 poste 34907
(EN) An Open-label, Multicenter, Phase 1b Study of JNJ-74494550 (Cusatuzumab; Anti-CD70 Monoclonal Antibody) in Combination With Background Therapy for the Treatment of Subjects With Acute Myeloid Leukemia
    ELEVATE
    NCT04150887
     Actif en recrutement
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
Henry Nchienzia
514-934-1934
(EN) A Randomized Pilot Trial Comparing Anti-Thymocyte Globulin (ATG) With ATG Plus Post Transplant Cyclophosphamide (PTCy) for Prophylaxis Against Acute and Chronic Graft Versus Host Disease (GVHD)
    CTTC 1901
    NCT04202835
     Actif en recrutement
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DE L'ENFANT-JESUS
Marie-Claude Lépine
418-649-0252 poste 63401
Banque des cellules leucémique du Québec
    banque cellules leucémique
     Actif en recrutement
CHU DE QUEBEC – UNIVERSITE LAVAL
L'HOTEL-DIEU DE QUEBEC ET CRCEO
Marie-Pierre Brochu
418-525-4444 poste 15768
Banque des cellules leucémique du Québec
    banque cellules leucémique
     Actif en recrutement
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DE L'ENFANT-JESUS
Linda Vallée
418-649-0252 poste 66602
(EN) A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/ITD AML
    2215-CL-0304
    NCT02997202
     Actif en recrutement
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
Manuel Rocha
514-934-1934 poste 35391
(EN) A Phase II Multi-center, Single Arm, Safety and Efficacy Study of Sabatolimab in Combination With Azacitidine and Venetoclax for the Treatment of Acute Myeloid Leukemia (AML) in Adult Patients Unfit for Chemotherapy
    STIMULUS-AML1
    NCT04150029
     Actif en recrutement
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS
Erika Thibault
514-340-8222